Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
2003 2
2006 3
2007 2
2008 5
2009 1
2010 1
2011 3
2012 5
2013 2
2014 3
2016 2
2017 2
2018 2
2019 3
2020 5
2021 6
2022 3
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Telmisartan, ramipril, or both in patients at high risk for vascular events.
ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. ONTARGET Investigators, et al. N Engl J Med. 2008 Apr 10;358(15):1547-59. doi: 10.1056/NEJMoa0801317. Epub 2008 Mar 31. N Engl J Med. 2008. PMID: 18378520 Free article. Clinical Trial.
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.
Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators; Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, et al. Lancet. 2008 Sep 27;372(9644):1174-83. doi: 10.1016/S0140-6736(08)61242-8. Epub 2008 Aug 29. Lancet. 2008. PMID: 18757085 Clinical Trial.
Magnetic Janssen effect.
Thorens L, Måløy KJ, Bourgoin M, Santucci S. Thorens L, et al. Among authors: bourgoin m. Nat Commun. 2021 Apr 30;12(1):2486. doi: 10.1038/s41467-021-22722-y. Nat Commun. 2021. PMID: 33931642 Free PMC article.
High caspase 3 and vulnerability to dual BCL2 family inhibition define ETO2::GLIS2 pediatric leukemia.
Aid Z, Robert E, Lopez CK, Bourgoin M, Boudia F, Le Mene M, Riviere J, Baille M, Benbarche S, Renou L, Fagnan A, Thirant C, Federici L, Touchard L, Lecluse Y, Jetten A, Geoerger B, Lapillonne H, Solary E, Gaudry M, Meshinchi S, Pflumio F, Auberger P, Lobry C, Petit A, Jacquel A, Mercher T. Aid Z, et al. Among authors: bourgoin m. Leukemia. 2023 Mar;37(3):571-579. doi: 10.1038/s41375-022-01800-0. Epub 2022 Dec 30. Leukemia. 2023. PMID: 36585521 Free PMC article.
Turbulent Properties of Stationary Flows in Porous Media.
Falkinhoff F, Ponomarenko A, Pierson JL, Gamet L, Volk R, Bourgoin M. Falkinhoff F, et al. Among authors: bourgoin m. Phys Rev Lett. 2024 Apr 26;132(17):174001. doi: 10.1103/PhysRevLett.132.174001. Phys Rev Lett. 2024. PMID: 38728704
Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001.
Montemagno C, Jacquel A, Pandiani C, Rastoin O, Dawaliby R, Schmitt T, Bourgoin M, Palenzuela H, Rossi AL, Ambrosetti D, Durivault J, Luciano F, Borchiellini D, Le Du J, Gonçalves LCP, Auberger P, Benhida R, Kinget L, Beuselinck B, Ronco C, Pagès G, Dufies M. Montemagno C, et al. Among authors: bourgoin m. J Exp Clin Cancer Res. 2024 Mar 19;43(1):86. doi: 10.1186/s13046-024-02984-2. J Exp Clin Cancer Res. 2024. PMID: 38504270 Free PMC article.
Broken Mirror Symmetry of Tracer's Trajectories in Turbulence.
Angriman S, Cobelli PJ, Bourgoin M, Huisman SG, Volk R, Mininni PD. Angriman S, et al. Among authors: bourgoin m. Phys Rev Lett. 2021 Dec 17;127(25):254502. doi: 10.1103/PhysRevLett.127.254502. Phys Rev Lett. 2021. PMID: 35029439
57 results